GRTS News and Press, Gritstone Oncology Inc. From 12/13/22

Clinical-stage biotech Gritstone bio ( NASDAQ: GRTS ) added ~13% in the morning hours Tuesday after the company announced that the U.S. regulators issued two new patents related to its self-amplifying mRNA (samRNA) vaccine platform technology. The U.S. Patent No. 11,504,421 issued...

EMERYVILLE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that the United States Patent and Trademark Office (USPTO) recently issued two new patents r...

Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed a new board member; Matthew J. Hawryluk, PhD, will “help support the company’s strategic initia...

EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., ( www.predictive-oncology.com ) to its Board of Directors to help support the company’s strategic initiatives and commercializat...

EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Gritstone management will participate in the following upcoming investor confer...

-- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response will now exceed 22 months – median not yet reached -- -- Patients who achieve a molecular response...

Gritstone Oncology press release ( NASDAQ: GRTS ): Q3 GAAP EPS of -$0.35. Revenue of $3.02M (+15.7% Y/Y). Cash, cash equivalents, marketable securities and restricted cash were $151.8 million as of September 30, 2022, compared to $223.5 million as of December 31, 2021....

-- Two Phase 1 CORAL (SARS-CoV-2) studies deliver positive results, provide further proof-of-concept for application of self-amplifying mRNA (samRNA) as infectious disease vaccine platform -- -- Initial Phase 2 data from KRAS-directed SLATE ("off-the-shelf" neoantigen program) s...

Gritstone bio ( NASDAQ: GRTS ) gained ~14% on Monday after Piper Sandler initiated its coverage with an Overweight recommendation, noting that the recently announced Phase 1 data for the biotech’s COVID-19 shot validates its vaccine technology for other infectious d...

Gritstone bio ( NASDAQ: GRTS ) on Tuesday said its self-amplifying mRNA (samRNA) COVID vaccine showed tolerability and immunogenicity in two phase 1 trials. CORAL-CEPI : The study includes 340 people and is evaluating T cell-enhanced omicron- and beta-s...